Litcius/Paper detail

Neutralization breadth of SARS-CoV-2 viral variants following primary series and booster SARS-CoV-2 vaccines in patients with cancer

Vivek Naranbhai, Kerri St. Denis, Evan C. Lam, Onosereme Ofoman, Wilfredo F. García-Beltrán, Cristhian Berrios Mairena, Atul K. Bhan, Justin F. Gainor, Alejandro B. Balazs, A. John Iafrate, Ryan J. Sullivan, Aditya Bardia, Laura M. Spring, Steven J. Isakoff, Jocelyn R. Farmer, Leyre Zubiri, Gabriella Hobbs, Joan How, Andrew M. Brunner, Amir T. Fathi, Clarie A. Pernat, Alexander Gavralidis, Jennifer Peterson, Mustafa Sakhi, Grace Hambelton, Elyssa N. Denault, Lindsey Mortensen, Lailoo A. Periello, Marissa N. Bruno, Marissa N. Bruno, Brittany Y. Betraux, Alyssa R. Lawless, Melissa A. Jackson, Elizabeth Niehoff, Claire Barabell, Christain N. Nambu, Erika Nakajima, T. L. Reinecke, Cyndi Bowes, Grace Kirkpatrick, Julia Thierauf, Kerri Reynolds, Henning Willers, Anand S. Dighe, Rebecca R. Saff, Kimberley Blumenthal

2022Cancer Cell36 citationsDOIOpen Access PDF

Topics & Concepts

NeutralizationBooster (rocketry)VaccinationVirologyAntibodyTiterSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Booster doseImmunologyImmune systemMedicineBiologyCoronavirus disease 2019 (COVID-19)DiseaseInfectious disease (medical specialty)Internal medicineAstronomyPhysicsSARS-CoV-2 and COVID-19 ResearchCOVID-19 and healthcare impactsCOVID-19 Clinical Research Studies
Neutralization breadth of SARS-CoV-2 viral variants following primary series and booster SARS-CoV-2 vaccines in patients with cancer | Litcius